Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy Adults

NCT06028347 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: sa-mRNA vaccine Dose 1
BIOLOGICAL: sa-mRNA vaccine Dose 2
BIOLOGICAL: sa-mRNA vaccine Dose 3
BIOLOGICAL: Placebo

Sponsor

Seqirus